公开(公告)号：US20230279097A1

公开(公告)日：2023-09-07

申请号：US18154116

申请日：2023-01-13

Applicant: Janssen Biotech, Inc.

Inventor： Matteo Cesaroni ,  Matthew Loza ,  Jarrat Jordan ,  Loqmane Seridi

IPC: C07K16/24 ,  G01N33/483 ,  G01N29/44 ,  C12Q1/6883 ,  A61K9/00 ,  A61P37/06 ,  G01N33/564 ,  A61K39/00

CPC classification number: C07K16/244 ,  G01N33/483 ,  G01N29/4418 ,  C07K16/249 ,  C12Q1/6883 ,  A61K9/0019 ,  A61P37/06 ,  G01N33/564 ,  C07K2317/21 ,  A61K2039/505 ,  C12Q2600/158 ,  C12Q2600/106 ,  G01N2333/555 ,  A61K2039/545 ,  C07K2317/76

Abstract: The present invention relates to methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20190352388A1

公开(公告)日：2019-11-21

申请号：US16415231

申请日：2019-05-17

Applicant: Janssen Biotech, Inc.

Inventor： Matteo Cesaroni ,  Matthew Loza ,  Jarrat Jordan ,  Loqmane Seridi

IPC: C07K16/24 ,  A61K9/00 ,  A61P37/06 ,  C12Q1/6883

Abstract: Methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with the anti-IL-12/IL-23p40 antibody ustekinumab.

公开(公告)号：US12009079B2

公开(公告)日：2024-06-11

申请号：US16663527

申请日：2019-10-25

Applicant: Janssen Biotech, Inc.

Inventor： Matteo Cesaroni ,  Marc Chevrier ,  Jarrat Jordan ,  Jessica Schreiter

IPC: C07K14/56 ,  C12Q1/6809 ,  G16H20/10 ,  G16H50/30

CPC classification number: G16H20/10 ,  C07K14/56 ,  C12Q1/6809 ,  G16H50/30 ,  C07K2317/565 ,  C12Q2539/00 ,  C12Q2545/114

Abstract: Type I interferon (IFN-I) signatures are useful in methods of diagnosing whether a subject (or patient) with IFN-I mediated disease will be responsive to treatment with an IFN-I inhibitor and treating or refraining from treating the subjects.

公开(公告)号：US11578124B2

公开(公告)日：2023-02-14

申请号：US16415231

申请日：2019-05-17

Applicant: Janssen Biotech, Inc.

Inventor： Matteo Cesaroni ,  Matthew Loza ,  Jarrat Jordan ,  Loqmane Seridi

IPC: C07K16/24 ,  A61K9/00 ,  A61P37/06 ,  G01N29/44 ,  G01N33/483 ,  G01N33/564 ,  C12Q1/6883 ,  A61K39/00

Abstract: Methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with the anti-IL-12/IL-23p40 antibody ustekinumab.